

ong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong  
take no responsibility for the contents of this announcement, make no  
ation as to its accuracy or completeness and expressly disclaim any liability  
er for any loss howsoever arising from or in reliance upon the whole or any  
contents of this announcement.



Hepalink

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED ISSUANCE OF CORPORATE BONDS  
AND  
CHANGE IN USE OF PROCEEDS**

**PROPOSED ISSUANCE OF CORPORATE BONDS**

On 30 June 2022, the Board of Directors (the "Board") of the Company (the "Company") (the "Corporate Bonds Issuance") (the "Corporate Bonds Issuance") (the "PRC-") (the "EGM-")

**1. ISSUE SIZE**

The Company has issued B1,000,000,000 (one billion RMB) (B1,000,000,000)

**2. TARGET SUBSCRIBERS**

B. / /

**3. TERM**

B. / / ( / )

**4. USE OF PROCEEDS**

(P) B. / /

**5. INTEREST RATE**

B. / / B. / /

**6. VALIDITY OF THE RESOLUTION(S)**

( ) / / 24 ( ) / / B. / /

**R a b P p I s s a**

B. / / B. / /

**PROPOSED CHANGE IN USE OF PROCEEDS**

**U.S. P** ( ) 24 2020 ( )  
**P** ( ) B /  
**(N P)** B3,538.4  
 2020 ( **G ba O** )  
 ( ) 30  
 2022 ( **I R p** ) 30  
 2022

**A** 30% B1,061.5  
 30% B1,061.5  
 20%  
 B707.7  
 20%  
 B707.7

**A** B1,115.2  
 30 2022  
 B2,423.2

| B   | C a U P              |                |                |                | E p    |
|-----|----------------------|----------------|----------------|----------------|--------|
|     | O a                  | U a a          | R a            | R a            |        |
| b   | P a                  | a a            | a a            | a a            | a a    |
|     | (RMB million)        | (RMB million)  | (RMB million)  | (RMB million)  | N P    |
| (1) | 1,061.5<br>(30% ...) | 1,034.4        | 27.1           |                |        |
| (2) | 1,061.5<br>(30% ...) |                | 1,061.5        | 636.9          | 24 ... |
| (3) | 707.7<br>(20% ...)   |                | 707.7          | 451.8          | 24 ... |
| (4) | 707.7<br>(20% ...)   | 80.8           | 626.9          | 376.2          | 24 ... |
| (5) |                      |                |                | 958.3          | 24 ... |
|     | <u>3,538.4</u>       | <u>1,115.2</u> | <u>2,423.2</u> | <u>2,423.2</u> |        |

R a a b P p C a U P

-19

2022

B

A

0.5 ( ) 1 ( ) 0.5 ( ) 4 ( ) 0.5 ( ) 10

B  
B  
24  
A  
B376.2

-19,  
2021 / 2022  
2022 / 31

A [faded text]

A [faded text]

[faded text]

B [faded text] B [faded text]  
S [faded text] H [faded text] P [faded text] a [faded text] a [faded text] a [faded text] G [faded text] [faded text] C [faded text] ., L [faded text] .  
L [faded text] L [faded text]  
Chairman

30 [faded text] 2022

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan and Mr. Shan Yu; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.*

\* *for identification purposes only*